MODULATION OF SIDE EFFECT PROFILE OF 5-ALPHA REDUCTASE INHIBITOR THERAPY
Methods for modulating one or more side effects of 5-α-reductase inhibitor therapy are provided, where the method includes administering a 5-α-reductase inhibitor and testosterone undecanoate. Also provided are methods of maintaining or restoring a DHT serum level in an individual undergoing 5-α-reductase inhibitor therapy, where the method includes administering testosterone undecanoate in addition to 5-α-reductase inhibitor. Further provided are methods of treating or preventing a DHT-related condition, such as benign prostate hyperplasia (BPH) or prostate cancer by administering a 5-α-reductase inhibitor and testosterone undecanoate.
1 . A method of modulating one or more side effects of 5-α-reductase inhibitor therapy, the method comprising administering:
a) a 5-α-reductase inhibitor; and
b) testosterone undecanoate;
wherein the administration of testosterone undecanoate is effective to modulate the one or more side effects of the 5-α-reductase inhibitor administration.
2 . The method of claim 1 , wherein the 5-α-reductase inhibitor is selected from dutasteride and finasteride.
3 . The method of claim 1 , wherein the modulating comprises decreasing the one or more side effects.
4 . The method of claim 1 , wherein the modulating comprises eliminating the one or more side effects.
5 . The method of claim 1 , wherein the one or more side effects include at least one effect selected from testicular sensitivity, diminishment of libido, erectile dysfunction, acne, increased dermal oil production, hair loss, alopecia, decreased sperm production, decreased ejaculatory function, gynecomastia, sarcopenia, and decrease in muscle mass.
6 . The method of claim 1 , wherein the modulating the one or more side effects comprises a decrease in the size, volume or weight of the seminal vesicles.
7 . The method of claim 1 , wherein the modulating the one or more side effects comprises a decrease in the size, volume or weight of the testes.
8 . A method of maintaining or restoring a serum DHT level in an individual undergoing 5-α-reductase inhibitor therapy, the method comprising administration of testosterone undecanoate in addition to the 5-α-reductase inhibitor.
9 . The method of claim 8 , wherein the administration of testosterone undecanoate in addition to the 5-α-reductase inhibitor is effective to achieve a serum DHT level of about 30 to about 300 ng/dL.
10 . The method of claim 8 , wherein the 5-α-reductase inhibitor is selected from dutasteride and finasteride.
11 . A method of treating or preventing a DHT-related condition, the method comprising administering:
a) a 5-α-reductase inhibitor; and
b) testosterone undecanoate.
12 . The method of claim 11 , wherein the DHT-related condition is selected from benign prostatic hyperplasia (BPH), prostate cancer, and DHT deficiency from prior prostate cancer treatment.
13 . The method of claim 11 , where the 5-α-reductase inhibitor is selected from dutasteride and finasteride.